Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

von Hippel-Lindau Disease × PT2385 × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 2 von Hippel-Lindau Disease 1 Kidney Neoplasms 1

Interventions

belzutifan 2 Everolimus 2 Blood Specimen Collection 2 tanespimycin 1 spartalizumab 1 palbociclib 1 lenvatinib 1 cabozantinib 1 PT2385 1 Oxygen-15 1 Nivolumab 1 Fluorodeoxyglucose F18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed

4 enrolled 11 charts

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡